Alembic Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)
Alembic Pharmaceuticals Ltd · Outcome · 04 Nov 2026, 7:56 pm
Alembic Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 2,603 (+36.3% YoY | +21.1% QoQ) ■ EBITDA: 563 (+78.4% YoY | +69.7% QoQ) ■ EBITDA Margin (%): 21.6 (+511 bps YoY | +620 bps QoQ) ■ PAT: 335 (+81.5% YoY | +93.7% QoQ) ■ EPS (INR): 17.1 (+81.4% YoY | +93.7% QoQ)
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. · 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. · 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). · 05 Nov 2026
- Please find attached Audio Recording of Investor Call. · 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. · 04 Nov 2026
- Please find attached Press Release · 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. · 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. · 04 Nov 2026
